Garvie CW, Wu X, Papanastasiou M, … Greulich H. Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase. Nat Comm, 2021; 12:4375.
Wu X, Schnitzler GR, Gao GF, … Greulich H. Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. J Biol Chem, 2020;295:3431-3446
de Waal L, Lewis TA, Rees MG, … Greulich H*, Meyerson M*. Identification of cancer cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol. 2016;12:102–108. *These authors contributed equally.
Heidi Greulich, Ph.D.
Heidi Greulich is a cancer biologist and senior group leader in the Cancer Program at the Broad Institute of MIT and Harvard. She leads a group that studies mutations in genes that lead to cancer, with the goal of developing new cancer therapies. Her current research focus is studying the mechanism of action of DNMDP, a small molecule that kills cancer cells expressing elevated levels of two genes, PDE3A and SLFN12. Her group also studies therapeutic approaches to EGFR-mutant lung cancer. Previous research at the Broad Institute includes characterization of oncogenic mutations in the extracellular domain of the receptor tyrosine kinase, ERBB2, novel oncogenic mutations of ARAF in NSCLC, FGFR2 mutations in endometrial cancer, and EGFR mutations in NSCLC.
Greulich joined the Broad Institute in 2004 with a joint affiliation with the Dana-Farber Cancer Institute, where she was a researcher and instructor for 12 years before switching her primary affiliation to the Broad Institute in 2016. She is the recipient of grants from Uniting Against Lung Cancer, Doctors Cancer Foundation, Lung Cancer Research Foundation, Exon20 Group, and the DOD CDMRP.
Greulich holds a Ph.D. in molecular oncology from The Rockefeller University and a bachelor’s degree in molecular biology from Princeton University. Her postdoctoral fellowship was undertaken at Harvard University.
Contact Heidi Greulich via email at firstname.lastname@example.org.